Buchanan Ingersoll & Rooney Represents Covis Pharma in Acquisition of Two Medicines from AstraZeneca

WASHINGTON, D.C. – January 10, 2022 – Buchanan Ingersoll & Rooney provided regulatory and intellectual property law advice to Covis Pharma Group, a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, in the company’s acquisition of two medicines from AstraZeneca. The two medicines are used for the treatment of chronic obstructive pulmonary disease (COPD) and are a strong compliment to the company's current product portfolio.

Barbara Binzak Blumenfeld, shareholder in the firm’s Life Sciences section and Matthew Fedowitz, shareholder in the firm’s Intellectual Property section advised Covis on this matter.

More information is available here.